Treatment of myelodysplastic syndromes with excess of blasts by bevacizumab is well tolerated and is associated with a decrease of VEGF plasma level

[1]  Jack Cuzick,et al.  Lancet Oncol 10 , 2013 .

[2]  J. Byrd,et al.  Effi cacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes : a randomised , open-label , phase III study , 2012 .

[3]  E. Scott,et al.  Leukemia regression by vascular disruption and antiangiogenic therapy. , 2010, Blood.

[4]  Valeria Santini,et al.  Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. , 2009, The Lancet. Oncology.

[5]  D. Ribatti.  Is angiogenesis essential for the progression of hematological malignancies or is it an epiphenomenon? , 2009, Leukemia.

[6]  Ø. Bruserud,et al.  Primary human acute myeloid leukaemia cells increase the proliferation of microvascular endothelial cells through the release of soluble mediators , 2009, British journal of haematology.

[7]  Bohuslav Melichar,et al.  Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial , 2007, The Lancet.

[8]  E. Perez,et al.  Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. , 2007, The New England journal of medicine.

[9]  H. Verheul,et al.  Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition , 2007, Nature Reviews Cancer.

[10]  W. Berdel,et al.  Bevacizumab reduces VEGF expression in patients with relapsed and refractory acute myeloid leukemia without clinical antileukemic activity , 2007, Leukemia.

[11]  Robert Gray,et al.  Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. , 2006, The New England journal of medicine.

[12]  B. Cheson,et al.  Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. , 2006, Blood.

[13]  Ma Dong,et al.  Bevacizumab plus Irinotecan,Fluorouracil,and Leucovorin for Metastatic Colorectal Cancer , 2006 .

[14]  J. Lancet,et al.  Acute myelogenous leukemia—microenvironment interactions: Role of endothelial cells and proteasome inhibition , 2005, Hematology.

[15]  J. Gribben,et al.  The role of the tumor microenvironment in hematological malignancies and implication for therapy. , 2005, Frontiers in bioscience : a journal and virtual library.

[16]  K. Podar,et al.  The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. , 2005, Blood.

[17]  D. Qian,et al.  Targeting Vascular Endothelial Growth Factor for Relapsed and Refractory Adult Acute Myelogenous Leukemias , 2004, Clinical Cancer Research.

[18]  Á. Aguayo.  The role of angiogenesis in the biology and therapy of myelodysplastic syndromes. , 2004, Current hematology reports.

[19]  Seth M Steinberg,et al.  A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. , 2003, The New England journal of medicine.

[20]  F. Kabbinavar,et al.  Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  S. Rafii,et al.  VEGF(165) promotes survival of leukemic cells by Hsp90-mediated induction of Bcl-2 expression and apoptosis inhibition. , 2002, Blood.

[22]  S. Rafii,et al.  Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy. , 2002, Blood.

[23]  H. Zwierzina,et al.  Blood levels of angiogenin and vascular endothelial growth factor are elevated in myelodysplastic syndromes and in acute myeloid leukemia. , 2002, Journal of hematotherapy & stem cell research.

[24]  W. Bellamy.  Expression of vascular endothelial growth factor and its receptors in multiple myeloma and other hematopoietic malignancies. , 2001, Seminars in oncology.

[25]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[26]  P. Korkolopoulou,et al.  Prognostic evaluation of the microvascular network in myelodysplastic syndromes , 2001, Leukemia.

[27]  M. Schapira,et al.  Endothelial cell activation by myeloblasts: molecular mechanisms of leukostasis and leukemic cell dissemination. , 2001, Blood.

[28]  T. Grogan,et al.  Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. , 2001, Blood.

[29]  G. Sledge,et al.  Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  B. Cheson,et al.  Report of an international working group to standardize response criteria for myelodysplastic syndromes. , 2000, Blood.

[31]  E. Estey,et al.  Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. , 2000, Blood.

[32]  S. Rafii,et al.  Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. , 2000, The Journal of clinical investigation.

[33]  W. Berdel,et al.  Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. , 2000, Blood.

[34]  S. Rafii,et al.  Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. , 2000, Blood.

[35]  G. Rodgers,et al.  Evidence of increased angiogenesis in patients with acute myeloid leukemia. , 2000, Blood.

[36]  G Flandrin,et al.  World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  G. Pruneri,et al.  Angiogenesis in myelodysplastic syndromes , 1999, British Journal of Cancer.

[38]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.

[39]  S. Ergün,et al.  Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. , 1997, Blood.

[40]  Y. Satow,et al.  Expression of the Vascular Endothelial Growth Factor ( VEGF ) Receptor Gene , KDR , in Hematopoietic Cells and Inhibitory Effect of VEGF on Apoptotic Cell Death Caused by Ionizing Radiation , 2022 .

[41]  H. Gralnick,et al.  Proposals for the classification of the myelodysplastic syndromes , 1982, British journal of haematology.